| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2079867 | Drug Discovery Today | 2015 | 4 Pages |
Abstract
- Clinical outcomes are the measure of quality in science.
- Much of the failure in biomarker discovery and validation is related to the way we understand and deliver molecular pathology activities.
- The current model for cancer discovery and treatment is not sustainable.
- An integrated model for molecular pathology provision is likely to overcome some of the existing barriers in biomarker validation and adoption.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Manuel Salto-Tellez, Richard D. Kennedy,